阿奇霉素对囊性纤维化婴儿结构性肺病的影响(COMBAT CF):一项3期随机双盲安慰剂对照临床试验
COMBAT CF是一项在澳大利亚和新西兰8个儿科囊性纤维化中心开展的3期随机双盲安慰剂对照试验,纳入新生儿筛查确诊的3-6月龄囊性纤维化婴儿130例,随机接受阿奇霉素10 mg/kg口服每周三次或安慰剂至36月龄。主要终点为影像学支气管扩张比例和病变累及肺容积百分比,36月龄时阿奇霉素组88% vs 安慰剂组94%存在支气管扩张(OR 0.49,95%CI 0.12-2.00;p=0.32),总气道病变无差异(中位差-0.02%,95%CI -0.59-0.56;p=0.96)。次要终点显示阿奇霉素组肺部急性加重住院天数更少(均差-6.3,95%CI -10.5至-2.1;p=0.0037)、吸入或口服抗生素疗程更少(发生率比0.88,95%CI 0.81-0.97;p=0.0088)。探索性分析显示36月龄时气道炎症标志物白介素-8和中性粒细胞弹性蛋白酶活性更低,但12月龄时无差异。作者认为每周三次阿奇霉素可考虑用于儿童囊性纤维化的常规早期管理。
要点
- 36月龄时阿奇霉素组88%(n=50)vs 安慰剂组94%(n=44)存在影像学支气管扩张,OR 0.49(95%CI 0.12-2.00;p=0.32),未达统计学显著。
- 阿奇霉素组肺部急性加重住院天数更少(均差-6.3,95%CI -10.5至-2.1;p=0.0037)。
- 阿奇霉素组吸入或口服抗生素疗程更少(发生率比0.88,95%CI 0.81-0.97;p=0.0088)。
- 36月龄时阿奇霉素组白介素-8(中位差-1.2 pg/mL,95%CI -1.9至-0.5;p=0.0012)和中性粒细胞弹性蛋白酶活性(-0.6 μg/mL,95%CI -1.1至-0.2;p=0.0087)更低,但12月龄时无差异。
- 作者建议每周三次阿奇霉素可考虑用于儿童囊性纤维化的常规早期管理。
适用人群与场景
- 新生儿筛查确诊的囊性纤维化婴儿,年龄3-6月龄,来自澳大利亚和新西兰8个儿科囊性纤维化中心。
- 排除标准包括生命最初3个月 prolonged 机械通气、除囊性纤维化外有临床显著意义的疾病或合并症、或大环内酯类过敏。
处置流程与药物剂量
- 阿奇霉素10 mg/kg体重口服,每周三次,从诊断起至36月龄。
- 对照组接受匹配的安慰剂。
研究设计与关键结果
- 3期随机双盲安慰剂对照试验,在澳大利亚和新西兰8个儿科囊性纤维化中心开展,筛查281例,纳入130例并随机分组接受首剂研究药物,阿奇霉素组68例,安慰剂组62例。
- 主要终点之一:36月龄时影像学支气管扩张比例,阿奇霉素组88%(n=50)vs 安慰剂组94%(n=44),OR 0.49(95%CI 0.12-2.00;p=0.32)。
- 主要终点之二:总气道病变累及肺容积百分比,两组无差异(中位差-0.02%,95%CI -0.59-0.56;p=0.96)。
- 次要终点:肺部急性加重住院天数,阿奇霉素组更少(均差-6.3,95%CI -10.5至-2.1;p=0.0037)。
- 次要终点:吸入或口服抗生素疗程,阿奇霉素组更少(发生率比0.88,95%CI 0.81-0.97;p=0.0088)。
- 探索性分析:36月龄时白介素-8浓度阿奇霉素组更低(中位差-1.2 pg/mL,95%CI -1.9至-0.5;p=0.0012),中性粒细胞弹性蛋白酶活性更低(-0.6 μg/mL,95%CI -1.1至-0.2;p=0.0087);12月龄时白介素-8和中性粒细胞弹性蛋白酶活性两组无差异。
- 36月龄时体重指数两组无差异(均差0.4,95%CI -0.1-0.9;p=0.12);使用阿奇霉素未观察到病原体出现的证据;不良结局少,两组无差异。
证据类型、等级与局限
- 证据类型:3期随机双盲安慰剂对照临床试验,意向性治疗分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 从囊性纤维化诊断起至36月龄每周三次阿奇霉素未减少36月龄时结构性肺病的范围。
- 作者认为每周三次阿奇霉素可考虑用于儿童囊性纤维化的常规早期管理,因其减少气道炎症、包括第一年肺部急性加重和住院的发病率,并改善部分与囊性纤维化肺病相关的临床结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Structural lung disease and neutrophil-dominated airway inflammation is present from 3 months of age in children diagnosed with cystic fibrosis after newborn screening. We hypothesised that azithromycin, given three times weekly to infants with cystic fibrosis from diagnosis until age 36 months, would reduce the extent of structural lung disease as captured on chest CT scans.
METHODS: A phase three, randomised, double-blind, placebo-controlled trial was done at eight paediatric cystic fibrosis centres in Australia and New Zealand. Infants (aged 3-6 months) diagnosed with cystic fibrosis following newborn screening were eligible. Exclusion criteria included prolonged mechanical ventilation in the first 3 months of life, clinically significant medical disease or comorbidities other than cystic fibrosis, or macrolide hypersensitivity. Participants were randomly assigned (1:1) to receive either azithromycin (10 mg/kg bodyweight orally three times per week) or matched placebo until age 36 months. Randomisation was done with a permuted block strategy and an interactive web-based response system, stratified by study site. Unblinding was done once all participants completed the trial. The two primary outcomes were the proportion of children with radiologically defined bronchiectasis, and the percentage of total lung volume affected by disease. Secondary outcomes included clinical outcomes and exploratory outcomes were inflammatory markers. Analyses were done with the intention-to-treat principle. This study is registered at ClinicalTrials.gov (NCT01270074).
FINDINGS: Between June 15, 2012, and July 10, 2017, 281 patients were screened, of whom 130 were enrolled, randomly assigned, and received first study dose. 68 participants received azithromycin and 62 received placebo. At 36 months, 88% (n=50) of the azithromycin group and 94% (n=44) of the placebo group had bronchiectasis (odds ratio 0·49, 95% CI 0·12 to 2·00; p=0·32), and total airways disease did not differ between groups (median difference -0·02%, 95% CI -0·59 to 0·56; p=0·96). Secondary outcome results included fewer days in hospital for pulmonary exacerbations (mean difference -6·3, 95% CI -10·5 to -2·1; p=0·0037) and fewer courses of inhaled or oral antibiotics (incidence rate ratio 0·88, 95% CI 0·81 to 0·97; p=0·0088) for those in the azithromycin group. For the preplanned, exploratory analysis, concentrations of airway inflammation were lower for participants receiving azithromycin, including interleukin-8 (median difference -1·2 pg/mL, 95% CI -1·9 to -0·5; p=0·0012) and neutrophil elastase activity (-0·6 μg/mL, -1·1 to -0·2; p=0·0087) at age 36 months, although no difference was noted between the groups for interleukin-8 or neutrophil elastase activity at 12 months. There was no effect of azithromycin on body-mass index at age 36 months (mean difference 0·4, 95% CI -0·1 to 0·9; p=0·12), nor any evidence of pathogen emergence with the use of azithromycin. There were few adverse outcomes with no differences between the treatment groups.
INTERPRETATION: Azithromycin treatment from diagnosis of cystic fibrosis did not reduce the extent of structural lung disease at 36 months of age; however, it did reduce airway inflammation, morbidity including pulmonary exacerbations in the first year of life and hospitalisations, and improved some clinical outcomes associated with cystic fibrosis lung disease. Therefore we suggest thrice-weekly azithromycin is a strategy that could be considered for the routine early management of paediatric patients with cystic fibrosis.
FUNDING: Cystic Fibrosis Foundation.
参考来源
- Stick SM, Foti A, Ware RS, et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respir Med. 2022. PMID: 35662406. doi:10.1016/S2213-2600(22)00165-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。